BriaCell Therapeutics (BriaCell Therapeutics) Cash-to-Debt : No Debt ⁽¹⁾ (As of Jan. 2024)

View and export this data going back to . Start your Free Trial

What is BriaCell Therapeutics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. BriaCell Therapeutics's cash to debt ratio for the quarter that ended in Jan. 2024 was No Debt ⁽¹⁾.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, BriaCell Therapeutics could pay off its debt using the cash in hand for the quarter that ended in Jan. 2024.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for BriaCell Therapeutics's Cash-to-Debt or its related term are showing as below:

BCTX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.02 Med: No Debt Max: No Debt
Current: No Debt

During the past 13 years, BriaCell Therapeutics's highest Cash to Debt Ratio was No Debt. The lowest was 0.02. And the median was No Debt.

BCTX's Cash-to-Debt is ranked better than
99.74% of 1538 companies
in the Biotechnology industry
Industry Median: 6.485 vs BCTX: No Debt

BriaCell Therapeutics Cash-to-Debt Historical Data

The historical data trend for BriaCell Therapeutics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

BriaCell Therapeutics Cash-to-Debt Chart

BriaCell Therapeutics Annual Data

Trend

Jul14

Jul15

Jul16

Jul17

Jul18

Jul19

Jul20

Jul21

Jul22

Jul23

Cash-to-Debt

Get a 7-Day Free Trial

0.49

0.05

2,202.65

No Debt

BriaCell Therapeutics Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Cash-to-Debt	Get a 7-Day Free Trial															No Debt	No Debt	No Debt	No Debt	No Debt

Competitive Comparison of BriaCell Therapeutics's Cash-to-Debt

For the Biotechnology subindustry, BriaCell Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BriaCell Therapeutics's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BriaCell Therapeutics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where BriaCell Therapeutics's Cash-to-Debt falls into.

BriaCell Therapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

BriaCell Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Jul. 2023 is calculated as:

BriaCell Therapeutics had no debt ⁽¹⁾.

BriaCell Therapeutics's Cash to Debt Ratio for the quarter that ended in Jan. 2024 is calculated as:

BriaCell Therapeutics had no debt ⁽¹⁾.

BriaCell Therapeutics (NAS:BCTX) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

BriaCell Therapeutics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of BriaCell Therapeutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

BriaCell Therapeutics (BriaCell Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BriaCell Therapeutics Corp (NAS:BCTX) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

BCT:Canada

Address

235 - 15th Street, Suite 300, West Vancouver, 3rd Floor, Bellevue Centre, Vancouver, BC, CAN, V7T 2X1

Website

https://www.briacell.com

BriaCell Therapeutics Corp is an immuno-oncology-focused biotechnology company. The group develops targeted and safe approaches for the management of cancer. BriaCell is conducting a Phase I/IIa clinical trial of Bria-IMT in metastatic breast cancer. Additionally, it is developing Bria-OTS, off-the-shelf personalized immunotherapy, for the treatment of advance-stage breast cancer by matching the patient's HLA type.

Executives

Jamieson Bondarenko	director	402-1 SCOTT ST.`, TORONTO A6 M5E 1A1
Jane A Gross	director	2401 4TH AVENUE, SUITE 1050, SEATTLE WA 98121
Rebecca Taub	director	750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111
Gadi Levin	officer: CFO & Secretary	MOSHAV AZRIEL 108, LEV HASHARON L3 4582500
Priore Giuseppe Del	officer: Chief Medical Officer	44 WALL STREET, 12TH FLOOR, NEW YORK NY 10005
Williams V. Williams	director, officer: President & CEO	620 SOUTH EAGLE ROAD, HAVERTOWN PA 19083
Martin E. Schmieg	director	201 S. 25TH STREET, APT. #521, PHILADELPHIA PA 19103
Miguel A. Lopez-lago	officer: Chief Scientific Officer	2401 PENNSYLVANIA AVE., APT #12A6, PHILADELPHIA PA 19130
Vaughn C. Embro-pantalony	director	P.O. BOX 58, 285 SUNSET BLVD, THORNBURY A6 N0H 2P0
Marc Lustig	director	4177 ROCKRIDGE ROAD, WEST VANCOUVER A1 V7W 1A3